Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT00203177 Completed - Parkinson's Disease Clinical Trials

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

Start date: October 2001
Phase: Phase 3
Study type: Interventional

Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.

NCT ID: NCT00203164 Completed - Parkinson's Disease Clinical Trials

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

Start date: May 2002
Phase: Phase 3
Study type: Interventional

This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.

NCT ID: NCT00203138 Completed - Parkinson's Disease Clinical Trials

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Start date: June 2004
Phase: Phase 3
Study type: Interventional

Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.

NCT ID: NCT00203125 Completed - Parkinson's Disease Clinical Trials

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Start date: October 2000
Phase: Phase 3
Study type: Interventional

This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo

NCT ID: NCT00203060 Completed - Parkinson's Disease Clinical Trials

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

Start date: July 1997
Phase: Phase 3
Study type: Interventional

Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.

NCT ID: NCT00203034 Completed - Parkinson's Disease Clinical Trials

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

Start date: May 2000
Phase: Phase 3
Study type: Interventional

Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

NCT ID: NCT00203008 Completed - Parkinson's Disease Clinical Trials

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Start date: January 2003
Phase: N/A
Study type: Observational

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

NCT ID: NCT00202657 Completed - Parkinson's Disease Clinical Trials

Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide

Start date: April 2005
Phase: Phase 4
Study type: Observational

The purpose of this study is to determine whether patients with Parkinson's disease and treated with pergolide have a higher risk of heart valve disease compared to patients with Parkinson's disease not treated with pergolide.

NCT ID: NCT00200447 Completed - Parkinson's Disease Clinical Trials

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses [123I]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

NCT ID: NCT00199433 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.